The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study

被引：0
作者：
Shao, Z. [1 ]
Huang, T. [2 ]
Fan, Z. [3 ]
Wang, Y. [4 ]
Yan, X. [5 ]
Yang, H. [6 ]
Wang, S. [7 ]
Pang, D. [8 ]
Li, H. [9 ]
Wang, H. [10 ]
Geng, C. [11 ]
Huang, L. [12 ]
Siddiqui, A. [13 ]
Wang, B. [14 ]
Xie, B. [15 ]
Sun, G. [16 ]
Restuccia, E. [17 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Breast Canc, Shanghai, Peoples R China
[2] Tongji Med Coll, Dept Breast & Thyroid Surg, Wuhan, Peoples R China
[3] Jilin Univ, Dept Breast Surg, Changchun, Peoples R China
[4] Shandong Canc Hosp, Breast Canc Ctr, Jinan, Peoples R China
[5] Sichuan Univ, West China Hosp, Med Oncol, Chengdu, Peoples R China
[6] Zhejiang Canc Hosp, Breast Surg, Hangzhou, Peoples R China
[7] Peking Univ Peoples Hosp, Breast Ctr, Beijing, Peoples R China
[8] Harbin Med Univ, Dept Breast Surg, Harbin, Peoples R China
[9] Beijing Canc Hosp, Breast Canc Ctr, Beijing, Peoples R China
[10] Affiliated Hosp Qingdao Univ, Dept Breast Ctr, Qingdao, Peoples R China
[11] Fourth Hosp Hebei Med Univ, Breast Ctr, Shijiazhuang, Hebei, Peoples R China
[12] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China
[13] Roche Prod Ltd, Prod Dev Clin Oncol, Welwyn Garden City, Herts, England
[14] Genentech Inc, Clin Pharmacol, San Francisco, CA 94080 USA
[15] Roche China Holding Co Ltd, Biostat, Shanghai, Peoples R China
[16] Roche China Holding Co Ltd, PD China, Shanghai, Peoples R China
[17] F Hoffmann La Roche Ltd, Prod Dev Oncol, Basel, Switzerland
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1MO
引用
收藏
页码：S1431 / S1431
页数：1
相关论文
共 50 条
  • [41] ANALYSIS OF NON-PHARMACOLOGICAL COST SAVINGS DERIVED FROM THE USE OF FIXED- DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS INJECTION IN PATIENTS WITH HER2POSITIVE BREAST CANCER IN SPAIN
    Calleja, T.
    Galve-Calvo, E.
    Gomez Agudo, E.
    Llaguno, J. L.
    Martin Rufo, M.
    Arroyo, I
    Lagunar Ruiz, J.
    Lores, M.
    Monzon, M.
    Saura, C.
    VALUE IN HEALTH, 2023, 26 (12) : S153 - S153
  • [42] Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference-Substudy of the randomised phase III GAIN-2 study
    Reinisch, Mattea
    Untch, Michael
    Mahlberg, Rolf
    Reimer, Toralf
    Hitschold, Thomas
    Marme, Frederik
    Aydogdu, Mustafa
    Schmatloch, Sabine
    Lueck, Hans-Joachim
    Schmidt, Marcus
    Ladda, Ekkehart
    Sinn, Bruno Valentin
    Klare, Peter
    Janni, Wolfgang
    Jackisch, Christian
    Denkert, Carsten
    Seiler, Sabine
    Goehler, Thomas
    Michel, Laura
    Burchardi, Nicole
    Stickeler, Elmar
    Rey, Julia
    Klutinus, Nicole
    Moebus, Volker
    Loibl, Sibylle
    BREAST, 2022, 66 : 110 - 117
  • [43] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Noguchi, Emi
    Tamura, Kenji
    Hattori, Masaya
    Horiguchi, Jun
    Sato, Nobuaki
    Kanatani, Kazumitsu
    Matsunaga, Kiyoshi
    Iwata, Hiroji
    Fujiwara, Yasuhiro
    BREAST CANCER, 2019, 26 (01) : 39 - 46
  • [44] Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study
    Zambetti, Milvia
    Montemurro, Filippo
    Morandi, Paolo
    Zamagni, Claudio
    Brandes, Alba A.
    Bisagni, Giancarlo
    Cagossi, Katia
    Bengala, Carmelo
    Gori, Stefania
    Iannacone, Claudio
    Stell, Alessia
    Gianni, Luca
    EUROPEAN JOURNAL OF CANCER, 2018, 105 : 61 - 70
  • [45] BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
    Dang, Chau
    Ewer, Michael S.
    Delaloge, Suzette
    Ferrero, Jean-Marc
    Colomer, Ramon
    de la Cruz-Merino, Luis
    Werner, Theresa L.
    Dadswell, Katherine
    Verrill, Mark
    Eiger, Daniel
    Sarkar, Sriparna
    de Haas, Sanne Lysbet
    Restuccia, Eleonora
    Swain, Sandra M.
    CANCERS, 2022, 14 (11)
  • [46] White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example COMMENT
    Jackisch, Christian
    Manevy, Federico
    Frank, Suzanne
    Roberts, Nicki
    Shafrin, Jason
    ADVANCES IN THERAPY, 2022, 39 (02) : 833 - 844
  • [47] A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer
    De Cock, Erwin
    Pivot, Xavier
    Hauser, Nik
    Verma, Sunil
    Kritikou, Persefoni
    Millar, Douglas
    Knoop, Ann
    CANCER MEDICINE, 2016, 5 (03): : 389 - 397
  • [48] The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program
    Pivot, X.
    Poole, C.
    Martin, M.
    Gligorov, J.
    Barrios, C. H.
    Vrdoljak, E.
    Zambetti, M.
    Woodward, N.
    Ten Tije, A. J.
    Lindegger, N.
    Crespel, G.
    Truman, M.
    Steger, G. G.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S105 - S106
  • [49] Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20)
    Masuda, N.
    Ohtani, S.
    Takano, T.
    Inoue, K.
    Suzuki, E.
    Nakamura, R.
    Bando, H.
    Ito, Y.
    Ishida, K.
    Yamanaka, T.
    Kuroi, K.
    Yasojima, H.
    Kasai, H.
    Takasuka, T.
    Sakurai, T.
    Kataoka, T. R.
    Morita, S.
    Ohno, S.
    Toi, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] ADDITIONAL SAFETY RESULTS OF HANNAH: A PHASE III RANDOMISED, OPEN-LABEL, INTERNATIONAL STUDY OF THE SUBCUTANEOUS FORMULATION OF TRASTUZUMAB (H) IN HER2-POSITIVE EARLY BREAST CANCER PATIENTS
    Jackisch, C.
    Dank, M.
    Frasci, G.
    Park, K. H.
    Lopez, R. I.
    Johnston, M.
    Heinzmann, D.
    Weber, H.
    Ismael, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 102 - 103
12345